Wedbush Maintains Outperform on Adicet Bio, Raises Price Target to $28

Wedbush analyst Robert Driscoll has maintained an 'Outperform' rating on Adicet Bio (NASDAQ: ACET) and raised the price target from $25 to $28. This adjustment reflects a positive outlook on the company's performance.